Literature DB >> 8420679

Hereditary ovarian cancer. Heterogeneity in age at onset.

H T Lynch1, P Watson, J F Lynch, T A Conway, M Fili.   

Abstract

BACKGROUND: Hereditary ovarian cancer (HOC) is heterogeneous, with at least three distinctive syndromes, namely, hereditary site-specific ovarian cancer, hereditary breast-ovarian cancer (HBOC) syndrome, and Lynch syndrome II. Ovarian cancer, in accord with virtually all varieties of adult onset cancer, displays an increasing incidence with advancing age; however, it shows an earlier age of onset in hereditary settings.
METHODS: Detailed medical and pathology studies were performed on extended ovarian cancer-prone pedigrees, with special attention given to age at ovarian cancer onset.
RESULTS: The age of onset of ovarian cancer is heterogeneous, wherein the average age of onset in HBOC is 52 years, in hereditary site-specific ovarian cancer it is 49 years, and in the Lynch syndrome II it is 45 years, in contrast to its occurrence in the general population, at an average age of 59 years.
CONCLUSIONS: These differences are important for the initiation of surveillance and management strategies. Age of onset of ovarian cancer differences in these several hereditary subsets are less striking than they are in the case of other integral forms of cancer in the respective syndromes, such as the breast in the HBOC syndrome. In addition, the phenomenon of extremely early age of onset of ovarian cancer occurs infrequently in HOC when compared to other forms of cancer, such as the breast in HBOC or the colon in Lynch syndrome II. Knowledge about age of onset heterogeneity in HOC may harbor important clues about etiology, pathogenesis, and cancer control.

Entities:  

Mesh:

Year:  1993        PMID: 8420679     DOI: 10.1002/cncr.2820710213

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

Review 1.  Müllerian intra-abdominal carcinomatosis in hereditary breast ovarian cancer syndrome: implications for risk-reducing surgery.

Authors:  Murray Joseph Casey; Agnes B Colanta
Journal:  Fam Cancer       Date:  2016-07       Impact factor: 2.375

2.  Family history in ovarian cancer referral population.

Authors:  L A Berg; S Robert Young; K A Brooks; A M Davis; S Terry Smith
Journal:  J Genet Couns       Date:  1996-03       Impact factor: 2.537

3.  Ovarian epithelial-stromal interactions: role of interleukins 1 and 6.

Authors:  Kamisha T Woolery; Patricia A Kruk
Journal:  Obstet Gynecol Int       Date:  2011-06-26

Review 4.  Cancer of the ovary, fallopian tube, and peritoneum: 2021 update.

Authors:  Jonathan S Berek; Malte Renz; Sean Kehoe; Lalit Kumar; Michael Friedlander
Journal:  Int J Gynaecol Obstet       Date:  2021-10       Impact factor: 4.447

5.  TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival.

Authors:  Pedro Kringen; Yun Wang; Vanessa Dumeaux; Jahn M Nesland; Gunnar Kristensen; Anne-Lise Borresen-Dale; Anne Dorum
Journal:  BMC Cancer       Date:  2005-10-17       Impact factor: 4.430

Review 6.  The role of the microbiome in ovarian cancer: mechanistic insights into oncobiosis and to bacterial metabolite signaling.

Authors:  Adrienn Sipos; Gyula Ujlaki; Edit Mikó; Eszter Maka; Judit Szabó; Karen Uray; Zoárd Krasznai; Péter Bai
Journal:  Mol Med       Date:  2021-04-01       Impact factor: 6.354

7.  Cancer incidence in the first-degree relatives of ovarian cancer patients.

Authors:  A Auranen; E Pukkala; J Mäkinen; R Sankila; S Grénman; T Salmi
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.